Nantahala Capital discloses 6.37% Korro Bio (KRRO) stake in Schedule 13G
Filing Impact
Filing Sentiment
Form Type
SCHEDULE 13G
Rhea-AI Filing Summary
Nantahala Capital Management, LLC and its principals reported a significant ownership stake in Korro Bio, Inc. As of December 31, 2025, they may be deemed to beneficially own 600,000 shares of Korro Bio common stock, representing 6.37% of the outstanding shares.
The shares are held by funds and separately managed accounts under Nantahala’s control, with Nantahala, Wilmot B. Harkey, and Daniel Mack sharing voting and dispositive power over all 600,000 shares. They state that the position is held in the ordinary course of business and not for the purpose of changing or influencing control of Korro Bio.
Positive
- None.
Negative
- None.
FAQ
What stake in Korro Bio (KRRO) does Nantahala Capital report on this Schedule 13G?
Nantahala Capital and its principals report beneficial ownership of 600,000 Korro Bio common shares, equal to 6.37% of the class as of December 31, 2025. The shares are held across funds and separately managed accounts under Nantahala’s control.
Who are the reporting persons on this Korro Bio (KRRO) Schedule 13G filing?
The reporting persons are Nantahala Capital Management, LLC, and its managing members Wilmot B. Harkey and Daniel Mack. Each may be deemed a beneficial owner of the same 600,000 Korro Bio common shares through funds and accounts managed by Nantahala.
As of what date is the Korro Bio (KRRO) ownership percentage calculated in this Schedule 13G?
The 6.37% ownership figure for Korro Bio is calculated as of December 31, 2025. On that date, the reporting persons may be deemed to beneficially own 600,000 shares of Korro Bio common stock through funds and accounts managed by Nantahala.
Is Nantahala Capital seeking to influence control of Korro Bio (KRRO) with this stake?
The reporting persons certify the Korro Bio shares were acquired and are held in the ordinary course of business. They state the holdings are not for the purpose of changing or influencing control of Korro Bio, except for activities solely related to a nomination under Rule 240.14a-11.
What type of security in Korro Bio (KRRO) is covered by this Schedule 13G?
The filing covers Korro Bio’s common stock with a par value of $0.001 per share, identified by CUSIP 500946108. The reporting persons collectively report beneficial ownership and shared voting and dispositive power over 600,000 shares of this common stock.